EGFR and cancer: In NSCLC patients with a pre-existent EGFR activating mutation, this last condition confers resistance to TKIs by sterically blocking the binding of drugs to the receptor pocket, thus giving an advantage to cancer cells by activating signaling pathways associated with tumor progression and metastasis (35).